Corvus Historical Income Statement
| CRVS Stock | USD 8.93 0.02 0.22% |
Historical analysis of Corvus Pharmaceuticals income statement accounts such as Interest Expense of 864.5 K, Selling General Administrative of 8.6 M or Total Revenue of 0.0 can show how well Corvus Pharmaceuticals performed in making a profits. Evaluating Corvus Pharmaceuticals income statement over time to spot trends is a great complementary tool to traditional technical analysis and can indicate the direction of Corvus Pharmaceuticals's future profits or losses.
Financial Statement Analysis is much more than just reviewing and examining Corvus Pharmaceuticals latest accounting reports to predict its past. Macroaxis encourages investors to analyze financial statements over time for various trends across multiple indicators and accounts to determine whether Corvus Pharmaceuticals is a good buy for the upcoming year.
Corvus |
About Corvus Income Statement Analysis
Corvus Pharmaceuticals Income Statement consists of revenues and expenses along with the resulting net income or loss. It represents the profit for the accounting period attributable to Corvus Pharmaceuticals shareholders. The income statement also shows Corvus investors and management if the firm made money during the period reported. The result of an income statement is the net income that is calculated after subtracting the expenses from revenue. It is essential to investors both as an absolute measure as well as earnings per share (i.e., EPS).
Corvus Pharmaceuticals Income Statement Chart
Add Fundamental
Gross Profit
Gross profit is a required income statement account that reflects total revenue of Corvus Pharmaceuticals minus its cost of goods sold. It is profit before Corvus Pharmaceuticals operating expenses, interest payments and taxes. Gross profit is also known as gross margin. The profit a company makes after deducting the costs associated with making and selling its products, or the costs associated with providing its services.Other Operating Expenses
Other Operating Expenses is the expense which generally does not depend on sales or production quantities of Corvus Pharmaceuticals. It is also known as Corvus Pharmaceuticals overhead expenses. Typically these expenses include marketing, rent and utilities, office, leases, and other overhead cost. Expenses incurred from non-core business activities, including administrative and general expenses, but excluding costs directly related to production.Total Operating Expenses
The total costs associated with the day-to-day operations of a business, excluding the cost of goods sold but including selling, general, and administrative expenses.Net Income
Net income is one of the most important fundamental items in finance. It plays a large role in Corvus Pharmaceuticals financial statement analysis. It represents the amount of money remaining after all of Corvus Pharmaceuticals operating expenses, interest, taxes and preferred stock dividends have been deducted from a company total revenue.Most accounts from Corvus Pharmaceuticals' income statement are interrelated and interconnected. However, analyzing income statement accounts one by one will only give a small insight into Corvus Pharmaceuticals current financial condition. On the other hand, looking into the entire matrix of income statement accounts, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Corvus Pharmaceuticals. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in real. For more information on how to buy Corvus Stock please use our How to Invest in Corvus Pharmaceuticals guide.At this time, Corvus Pharmaceuticals' Selling General Administrative is comparatively stable compared to the past year. Other Operating Expenses is likely to gain to about 37.8 M in 2024, whereas Interest Expense is likely to drop slightly above 864.5 K in 2024.
Corvus Pharmaceuticals income statement Correlations
Click cells to compare fundamentals
Corvus Pharmaceuticals Account Relationship Matchups
High Positive Relationship
High Negative Relationship
Corvus Pharmaceuticals income statement Accounts
| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
| Depreciation And Amortization | 743K | 632K | 460K | 367K | 151K | 143.5K | |
| Interest Expense | 2.2M | 540K | 15K | 654K | 1.6M | 864.5K | |
| Selling General Administrative | 10.9M | 11.9M | 9.5M | 8.1M | 6.9M | 8.6M | |
| Gross Profit | (743K) | (632K) | (460K) | (367K) | (151K) | (158.6K) | |
| Other Operating Expenses | 48.9M | 43.8M | 38.6M | 32.6M | 23.4M | 37.8M | |
| Operating Income | (48.9M) | (43.8M) | (38.6M) | (32.6M) | (23.3M) | (24.5M) | |
| Net Income From Continuing Ops | (46.7M) | (6.0M) | (43.2M) | (41.3M) | (30.2M) | (31.7M) | |
| Ebit | (48.9M) | (43.8M) | (43.2M) | (41.3M) | (27.0M) | (28.4M) | |
| Research Development | 38.0M | 31.8M | 29.1M | 24.5M | 16.5M | 29.2M | |
| Cost Of Revenue | 743K | 632K | 460K | 367K | 151K | 143.5K | |
| Total Operating Expenses | 48.9M | 43.8M | 38.6M | 32.6M | 23.4M | 37.8M | |
| Income Before Tax | (46.7M) | (6.0M) | (43.2M) | (41.3M) | (27.0M) | (28.4M) | |
| Total Other Income Expense Net | 2.2M | 37.8M | (4.6M) | (8.7M) | (3.7M) | (3.5M) | |
| Net Income Applicable To Common Shares | (46.7M) | (6.0M) | (43.2M) | (41.3M) | (37.2M) | (39.0M) | |
| Net Income | (43.7M) | (4.8M) | (38.2M) | (50.0M) | (27.0M) | (28.4M) | |
| Income Tax Expense | (2.9M) | (1.2M) | (5.0M) | 8.7M | 10.1M | 10.6M | |
| Interest Income | 2.3M | 2.2M | 540K | 6K | 5.4K | 5.1K | |
| Ebitda | (48.1M) | (43.1M) | (42.8M) | (40.9M) | (26.9M) | (28.2M) | |
| Net Interest Income | 2.2M | 540K | (15K) | 654K | 1.5M | 862.8K | |
| Reconciled Depreciation | 743K | 632K | 460K | 367K | 217K | 206.2K |
Thematic Opportunities
Explore Investment Opportunities
Additional Tools for Corvus Stock Analysis
When running Corvus Pharmaceuticals' price analysis, check to measure Corvus Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Corvus Pharmaceuticals is operating at the current time. Most of Corvus Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Corvus Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Corvus Pharmaceuticals' price. Additionally, you may evaluate how the addition of Corvus Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.